메뉴 건너뛰기




Volumn 76, Issue 6, 1997, Pages 797-804

High dose mitoxantrone with peripheral blood progenitor cell rescue: Toxicity, pharmacokinetics and implications for dosage and schedule

Author keywords

High dose chemotherapy; Mitoxantrone; Peripheral blood progenitor cells

Indexed keywords

MELPHALAN; MITOXANTRONE;

EID: 12644255675     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.465     Document Type: Article
Times cited : (16)

References (28)
  • 2
    • 0028115696 scopus 로고
    • Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation
    • Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J and Laurent G (1994) Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol 12: 141-148
    • (1994) J Clin Oncol , vol.12 , pp. 141-148
    • Attal, M.1    Canal, P.2    Schlaifer, D.3    Chatelut, E.4    Dezeuze, A.5    Huguet, F.6    Payen, C.7    Pris, J.8    Laurent, G.9
  • 3
    • 0027453573 scopus 로고
    • Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer
    • Bowers C, Adkins D, Dunphy F, Harrison B, LeMaistre CF and Spitzer G (1993) Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Bone Marrow Transplant 12: 525-530
    • (1993) Bone Marrow Transplant , vol.12 , pp. 525-530
    • Bowers, C.1    Adkins, D.2    Dunphy, F.3    Harrison, B.4    LeMaistre, C.F.5    Spitzer, G.6
  • 6
    • 0025651011 scopus 로고
    • A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating dose of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies
    • Ellis ED, William SF, Moormeier JA, Kaminer LS and Bitran JD (1990) A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating dose of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplant 6: 439-442
    • (1990) Bone Marrow Transplant , vol.6 , pp. 439-442
    • Ellis, E.D.1    William, S.F.2    Moormeier, J.A.3    Kaminer, L.S.4    Bitran, J.D.5
  • 7
    • 0027429618 scopus 로고
    • Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia
    • Feldman EJ, Alberts DS, Arlin Z, Ahmed A, Mittelman A, Baskind, Peng Y-M, Baier M and Plezia P (1993) Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11: 2002-2009
    • (1993) J Clin Oncol , vol.11 , pp. 2002-2009
    • Feldman, E.J.1    Alberts, D.S.2    Arlin, Z.3    Ahmed, A.4    Mittelman, A.5    Baskind6    Peng, Y.-M.7    Baier, M.8    Plezia, P.9
  • 8
    • 0022492174 scopus 로고
    • Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells
    • Fountzilas G, Ohnuma T, Rammos K, Mindich B and Holland FJ (1986) Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. Cancer Drug Delivery 3: 93-100
    • (1986) Cancer Drug Delivery , vol.3 , pp. 93-100
    • Fountzilas, G.1    Ohnuma, T.2    Rammos, K.3    Mindich, B.4    Holland, F.J.5
  • 9
    • 0023729443 scopus 로고
    • When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?
    • Freedman LS and Workman P (1988) When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? Cancer Chemother Pharmacol 22: 95-103
    • (1988) Cancer Chemother Pharmacol , vol.22 , pp. 95-103
    • Freedman, L.S.1    Workman, P.2
  • 10
    • 0002991458 scopus 로고
    • Pharmacologic strategies for high-dose chemotherapy
    • Armitage JO and Antman KH (eds), Williams & Wilkins: Baltimore
    • Frei E (1995) Pharmacologic strategies for high-dose chemotherapy. In High-dose Cancer Therapy. Armitage JO and Antman KH (eds), pp. 3-16. Williams & Wilkins: Baltimore
    • (1995) High-dose Cancer Therapy , pp. 3-16
    • Frei, E.1
  • 11
    • 0018931869 scopus 로고
    • Dose: A critical factor in cancer therapy
    • Frei E and Canellos GP (1980) Dose: A critical factor in cancer therapy. Am J Med 69: 585-594
    • (1980) Am J Med , vol.69 , pp. 585-594
    • Frei, E.1    Canellos, G.P.2
  • 13
    • 0024380739 scopus 로고
    • High-dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery?
    • Gianni AM and Bonadonna G (1989) High-dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 25: 1027-1030
    • (1989) Eur J Cancer Clin Oncol , vol.25 , pp. 1027-1030
    • Gianni, A.M.1    Bonadonna, G.2
  • 16
    • 0027772976 scopus 로고
    • Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony-stimulating factor and interleukin3 on hematopoietic progenitors in human long-term bone marrow cultures
    • Lemoli RM and Gulati SC (1993) Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony-stimulating factor and interleukin3 on hematopoietic progenitors in human long-term bone marrow cultures. Stem Cells 11: 435-444
    • (1993) Stem Cells , vol.11 , pp. 435-444
    • Lemoli, R.M.1    Gulati, S.C.2
  • 17
    • 0029561265 scopus 로고
    • High-dose chemotherapy for breast cancer: Clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT)
    • Martin M (1995) High-dose chemotherapy for breast cancer: clinical advantages of autologous peripheral blood progenitor cells (PBPC) compared with autologous bone marrow transplantation (ABMT) Ann Oncol 6 (suppl. 4): S33-S37
    • (1995) Ann Oncol , vol.6 , Issue.4 SUPPL.
    • Martin, M.1
  • 18
    • 0024411287 scopus 로고
    • High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors
    • Mulder POM, Sleijfer DT, Willemse PHB, De Vries EGE, Uges DRA and Mulder NH (1989) High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 49: 4654-4658
    • (1989) Cancer Res , vol.49 , pp. 4654-4658
    • Mulder, P.O.M.1    Sleijfer, D.T.2    Willemse, P.H.B.3    De Vries, E.G.E.4    Uges, D.R.A.5    Mulder, N.H.6
  • 20
    • 0020333639 scopus 로고
    • Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone
    • Peng YM, Ormberg D and Alberts DS (1982) Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. J Chromatog Biomed Appl 233: 235-247
    • (1982) J Chromatog Biomed Appl , vol.233 , pp. 235-247
    • Peng, Y.M.1    Ormberg, D.2    Alberts, D.S.3
  • 23
    • 0027383240 scopus 로고
    • Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s)
    • Siena S, Bregni M, Bonsi L, Strippoli P, Peccatori F, Magni M, Di Nicola M, Bagnara GP and Gianni AM (1993) Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). Stem Cells 11 (suppl. 2): 72-75
    • (1993) Stem Cells , vol.11 , Issue.2 SUPPL. , pp. 72-75
    • Siena, S.1    Bregni, M.2    Bonsi, L.3    Strippoli, P.4    Peccatori, F.5    Magni, M.6    Di Nicola, M.7    Bagnara, G.P.8    Gianni, A.M.9
  • 24
    • 0027952666 scopus 로고
    • Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma
    • Stiff PJ, McKenzie RS, Alberts DS, Sosman JA, Dolan JR, Rad N and McCloskey T (1994) Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 12: 176-183
    • (1994) J Clin Oncol , vol.12 , pp. 176-183
    • Stiff, P.J.1    McKenzie, R.S.2    Alberts, D.S.3    Sosman, J.A.4    Dolan, J.R.5    Rad, N.6    McCloskey, T.7
  • 25
    • 0027444652 scopus 로고
    • A predictive model for aggressive non-Hodgkin's lymphoma
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987-994
    • (1993) N Engl J Med , vol.329 , pp. 987-994


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.